HILDEN, Germany, February 15, 2016 /PRNewswire/ --
Cross-European trial shows enhanced sensitivity of fourth-generation test for tuberculosis infection
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a major published study evaluating its novel QuantiFERON®-TB Gold Plus, the fourth-generation of QIAGEN's industry-leading test for tuberculosis (TB) infection. Results of the multi-center study, published ahead of print in the peer-reviewed European Respiratory Journal on February 12, confirmed that QuantiFERON-TB Gold Plus demonstrates excellent performance,- with a diagnostic sensitivity estimated at 88% and a specificity of 97%. Notably, among subjects co-infected with HIV and TB, the QuantiFERON-TB Gold Plus result was positive in all of them, demonstrating 100% sensitivity in this challenging patient population.
"This publication by leading European experts provides the medical community with independent confirmation of the excellent performance of QuantiFERON-TB Gold Plus as demonstrated in our validation and registration studies," said Dr. Masae Kawamura, Senior Director of Medical and Scientific Affairs for QIAGEN. "Introduced in Europe in 2015, QuantiFERON-TB Gold Plus helps clinicians get accurate, reliable results to detect latent TB infection and to protect vulnerable patients from active TB. The authors also noted the potential value of additional clinical information provided by the proprietary CD8 T-cell technology in QuantiFERON TB-Gold Plus."
Click here for full press release
Public Relations:
Dr. Thomas Theuringer
Director Public Relations
+49-2103-29-11826
Email: pr@qiagen.com
www.twitter.com/qiagen
https://www.facebook.com/QIAGEN
pr.qiagen.com
Investor Relations:
John Gilardi
Vice President Corporate Communications and Investor Relations
+49-2103-29-11711
Email: ir@qiagen.com
ir.qiagen.com
